Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?

References

• EkbomKARestless legsActa Med Scand1945158Suppl1123
   Google Scholar
• AllenRPPicchiettiDHeningWATrenkwalderCWaltersASMontplaisiJRestless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study GroupRestless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of HealthSleep Med20034210111914592341
   PubMed Web of Science ®Google Scholar
• TunçTKaradağYSDoğuluFInanLEPredisposing factors of restless legs syndrome in pregnancyMov Disord200722562763117285614
   PubMed Web of Science ®Google Scholar
• AllenRPEarleyCJThe role of iron in restless legs syndromeMov Disord200722Suppl 18S440S44817566122
   PubMed Web of Science ®Google Scholar
• GigliGLAdoratiMDolsoPRestless legs syndrome in end-stage renal diseaseSleep Med20045330931515165541
   PubMed Web of Science ®Google Scholar
• GemignaniFBrindaniFNegrottiAVitettaFAlfieriSMarbiniARestless legs syndrome and polyneuropathyMov Disord20062181254125716685701
   PubMed Web of Science ®Google Scholar
• ManconiMGovoniVDe VitoARestless legs syndrome and pregnancyNeurology20046361065106915452299
   PubMed Web of Science ®Google Scholar
• AllenRPWaltersASMontplaisirJRestless legs syndrome prevalence and impact: REST general population studyArch Intern Med2005165111286129215956009
   PubMedGoogle Scholar
• HeningWWaltersASAllenRPMontplaisirJMyersAFerini-StrambiLImpact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care studySleep Med20045323724615165529
   PubMed Web of Science ®Google Scholar
• OhayonMMO’HaraRVitielloMVEpidemiology of restless legs syndrome: a synthesis of the literatureSleep Med Rev201216428329521795081
   PubMed Web of Science ®Google Scholar
• InnesKESelfeTKAgarwalPPrevalence of restless legs syndrome in North American and Western European populations: a systematic reviewSleep Med201112762363421752711
   PubMed Web of Science ®Google Scholar
• AllenRPBharmalMCallowayMPrevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United StatesMov Disord201126111412021322022
   PubMed Web of Science ®Google Scholar
• AllenRPStillmanPMyersAJPhysician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristicsSleep Med2010111313719464949
   PubMed Web of Science ®Google Scholar
• NomuraTInoueYKusumiMEmail-based epidemiological surveys on restless legs syndrome in JapanSleep Biol Rhythm20086139145
   Web of Science ®Google Scholar
• NomuraTInoueYKusumiMUemuraYNakashimaKPrevalence of restless legs syndrome in a rural community in JapanMov Disord200823162363236918973260
   PubMed Web of Science ®Google Scholar
• MizunoSMiyaokaTInagakiTHoriguchiJPrevalence of restless legs syndrome in non-institutionalized Japanese elderlyPsychiatry Clin Neurosci200559446146516048452
   PubMed Web of Science ®Google Scholar
• Garcia-BorregueroDKohnenRSilberMHThe long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study GroupSleep Med201314767568423859128
   PubMed Web of Science ®Google Scholar
• SilberMHEhrenbergBLAllenRPMedical Advisory Board of the Restless Legs Syndrome FoundationAn algorithm for the management of restless legs syndromeMayo Clin Proc200479791692215244390
   PubMed Web of Science ®Google Scholar
• OertelWHTrenkwalderCZucconiMState of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndromeMov Disord200722Suppl 18S466S47517516455
   PubMed Web of Science ®Google Scholar
• TrenkwalderCHeningWAMontagnaPTreatment of restless legs syndrome: an evidence-based review and implications for clinical practiceMov Disord200823162267230218925578
   PubMed Web of Science ®Google Scholar
• HeningWACurrent guidelines and standards of practice for restless legs syndromeAm J Med20071201 Suppl 1S22S2717198767
   PubMed Web of Science ®Google Scholar
• VignatelliLBilliardMClarenbachPEFNS Task ForceEFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleepEur J Neurol200613101049106516987157
   PubMed Web of Science ®Google Scholar
• BliwiseDLFreemanAIngramCDRyeDBChakravortySWattsRLRandomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndromeSleep Med20056214114715716217
   PubMed Web of Science ®Google Scholar
• AllenRBeckerPMBoganRRopinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndromeSleep200427590791415453549
   PubMed Web of Science ®Google Scholar
• PartinenMHirvonenKJamaLEfficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study – the PRELUDE studySleep Med20067540741716815748
   PubMed Web of Science ®Google Scholar
• García-BorregueroDAllenRPBenesHAugmentation as a treatment complication of restless legs syndrome: concept and managementMov Disord200722Suppl 18S476S48417580331
   PubMed Web of Science ®Google Scholar
• García-BorregueroDWilliamsAMDopaminergic augmentation of restless legs syndromeSleep Med Rev201014533934620219397
   PubMed Web of Science ®Google Scholar
• Horizant® (gabapentin enacarbil) [prescribing information]Santa Clara, CAXenoPort, Inc. revised52013
   Google Scholar
• HendrichJVan MinhATHeblichFPharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentinProc Natl Acad Sci U S A200810593628363318299583
   PubMed Web of Science ®Google Scholar
• DooleyDJTaylorCPDonevanSFeltnerDCa2+ channel alpha2delta ligands: novel modulators of neurotransmissionTrends Pharmacol Sci2007282758217222465
   PubMed Web of Science ®Google Scholar
• Garcia-BorregueroDFerini-StrambiLKohnenREuropean Federation of Neurological SocietiesEuropean Neurological SocietyEuropean Sleep Research SocietyEuropean guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research SocietyEur J Neurol201219111385139622937989
   PubMed Web of Science ®Google Scholar
• ThorpMLMorrisCDBagbySPA crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patientsAm J Kidney Dis200138110410811431189
   PubMed Web of Science ®Google Scholar
• HappeSSauterCKlöschGSaletuBZeitlhoferJGabapentin versus ropinirole in the treatment of idiopathic restless legs syndromeNeuropsychobiology2003482828614504416
   PubMed Web of Science ®Google Scholar
• MicozkadiogluHOzdemirFNKutASezerSSaatciUHaberalMGabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label studyRen Fail200426439339715462107
   PubMed Web of Science ®Google Scholar
• Garcia-BorregueroDLarrosaOde la LlaveYVergerKMasramonXHernandezGTreatment of restless legs syndrome with gabapentin: a double-blind, cross-over studyNeurology200259101573157912451200
   PubMed Web of Science ®Google Scholar
• Neurontin® (gabapentin) [prescribing information]New YorkPfizer, Inc. revised122012
   Google Scholar
• GidalBERadulovicLLKrugerSRuteckiPPitterleMBockbraderHNInter- and intra-subject variability in gabapentin absorption and absolute bioavailabilityEpilepsy Res2000402–312312710863139
   PubMed Web of Science ®Google Scholar
• StewartBHKuglerARThompsonPRBockbraderHNA saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasmaPharm Res19931022762818456077
   PubMed Web of Science ®Google Scholar
• LalRSukbuntherngJLuoWPharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteersClin Ther20093181776178619808136
   PubMed Web of Science ®Google Scholar
• XenoPort, IncGabapentin Enacarbil (GSK1838262) Adult Restless Legs Syndrome Post Marketing Commitment Study (CONCORD) Available from: http://clinicaltrials.gov/ct2/show/NCT01668667?term=concord&rank=1Accessed: January 6, 2014
   Google Scholar
• LalRSukbuntherngJLuoWClinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic studyClin Ther201234120121322206794
   PubMed Web of Science ®Google Scholar
• CundyKCSastrySLuoWZouJMoorsTLCanafaxDMClinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentinJ Clin Pharmacol200848121378138818827074
   PubMed Web of Science ®Google Scholar
• LalREllenbogenAChenDA randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndromeClin Neuropharmacol201235416517322664749
   PubMed Web of Science ®Google Scholar
• CundyKCAnnamalaiTBuLXP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeysJ Pharmacol Exp Ther2004311132433315146029
   PubMed Web of Science ®Google Scholar
• CundyKCBranchRChernov-RoganTXP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transportersJ Pharmacol Exp Ther2004311131532315146028
   PubMed Web of Science ®Google Scholar
• LalRSukbuntherngJLuoWHuffFJZouJCundyKCThe effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbilInt J Clin Pharmacol Ther201048212012820137764
   PubMed Web of Science ®Google Scholar
• LalRSukbuntherngJHoJCundyKCA phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteersInt J Clin Pharmacol Ther201149210911521255527
   PubMed Web of Science ®Google Scholar
• LalRSukbuntherngJLuoWClinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic studyClin Ther201234120121322206794
   PubMed Web of Science ®Google Scholar
• ChenCMeta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbilEur J Clin Pharmacol201369101809181723743781
   PubMed Web of Science ®Google Scholar
• KushidaCAWaltersASBeckerPXP021 Study GroupA randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndromeSleep200932215916819238802
   PubMed Web of Science ®Google Scholar
• WaltersASOndoWGKushidaCAXP045 Study GroupGabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trialClin Neuropharmacol200932631132019667976
   PubMed Web of Science ®Google Scholar
• KushidaCABeckerPMEllenbogenALCanafaxDMBarrettRWXP052 Study GroupRandomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLSNeurology200972543944619188575
   PubMed Web of Science ®Google Scholar
• LeeDOZimanRBPerkinsATPocetaJSWaltersASBarrettRWXP053 Study GroupA randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndromeJ Clin Sleep Med20117328229221677899
   PubMed Web of Science ®Google Scholar
• BoganRKBornemannMAKushidaCATrânPVBarrettRWXP060 Study GroupLong-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled studyMayo Clin Proc201085651252120511481
   PubMed Web of Science ®Google Scholar
• EllenbogenALTheinSGWinslowDHA 52-week study of gabapentin enacarbil in restless legs syndromeClin Neuropharmacol201134181621242741
   PubMed Web of Science ®Google Scholar
• WinkelmanJWBoganRKSchmidtMHHudsonJDDeRossettSEHill-ZabalaCERandomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndromeMov Disord201126112065207221611981
   PubMed Web of Science ®Google Scholar
• VanMeterSAKavanaghSTWarrenSBarrettRWDose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studiesCNS Drugs201226977378022849331
   PubMed Web of Science ®Google Scholar
• LalRSukbuntherngJLuoWToveraJLassauzetMLCundyKCPopulation pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbilJ Clin Pharmacol2013531294023400741
   PubMed Web of Science ®Google Scholar
• BoganRKEllenbogenABeckerPMGabapentin enacarbil in subjects with moderate to severe primary restless legs syndrome with and without severe sleep disturbance: an integrated analysis of subjective and novel sleep endpoints from two studiesJ Parkinsonism Restless Legs Syndrome201333140
   Google Scholar
• InoueYUchimuraNKurodaKHirataKHattoriNLong-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patientsProg Neuropsychopharmacol Biol Psychiatry201236225125722036917
   PubMed Web of Science ®Google Scholar
• InoueYHirataKUchimuraNKurodaKHattoriNTakeuchiMGabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group studyCurr Med Res Opin2013291132123121149
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and ResearchApplication number: 022399Orig1s000 Medical Review Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022399Orig1s000MedR.pdfAccessed: January 6, 2014
   Google Scholar
• Center for Drug Evaluation and ResearchApplication number: 022399Orig1s000 Summary Review Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022399Orig1s000SumR.pdfAccessed: January 6, 2014
   Google Scholar
• IrizarryMCWebbDJBoudiafNRisk of cancer in patients exposed to gabapentin in two electronic medical record systemsPharmacoepidemiol Drug Saf201221221422522144034
   PubMed Web of Science ®Google Scholar
• KohnenRAllenRPBenesHAssessment of restless legs syndrome – methodological approaches for use in practice and clinical trialsMov Disord200722Suppl 18S485S49417534967
   PubMed Web of Science ®Google Scholar
• Stiasny-KolsterKBenesHPeglauIEffective cabergoline treatment in idiopathic restless legs syndromeNeurology200463122272227915623686
   PubMed Web of Science ®Google Scholar
• FuldaSWetterTCWhere dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studiesBrain2008131490291717932100
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and ResearchApplication number: 022399Orig1s000 Pharmacology Review Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022399Orig1s000PharmR.pdfAccessed: January 6, 2014
   Google Scholar
• Center for Drug Evaluation and ResearchApplication number: 022399Orig1s000 Cross Discipline Team Leader Review Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022399Orig1s000CrossR.pdfAccessed: January 6, 2014
   Google Scholar
• LiYWaltersASChiuveSERimmEBWinkelmanJWGaoXProspective study of restless legs syndrome and coronary heart disease among womenCirculation2012126141689169422967852
   PubMed Web of Science ®Google Scholar
• InnesKESelfeTKAgarwalPRestless legs syndrome and conditions associated with metabolic dysregulation, sympathoadrenal dysfunction, and cardiovascular disease risk: a systematic reviewSleep Med Rev201216430933921733722
   PubMed Web of Science ®Google Scholar
• Tippmann-PeikertMParkJGBoeveBFShepardJWSilberMHPathologic gambling in patients with restless legs syndrome treated with dopaminergic agonistsNeurology200768430130317242339
   PubMed Web of Science ®Google Scholar
• Driver-DunckleyEDNobleBNHentzJGGambling and increased sexual desire with dopaminergic medications in restless legs syndromeClin Neuropharmacol200730524925517909302
   PubMed Web of Science ®Google Scholar
• VoonVSchoerlingAWenzelSFrequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndromeBMC Neurol20111111721955669
   PubMed Web of Science ®Google Scholar